PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Study Summary

This Phase 1b study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of multiple IV infusions of PMN310 in patients with early Alzheimer's disease.

Conditions

Alzheimer Disease, Early Onset

Interventions / Drugs

PMN310 Placebo

View on ClinicalTrials.gov ↗

Sponsor

PMN

ProMIS Neurosciences

Misfolded Protein ALS/AD

D42/100

Study Details

Enrollment144 participants

Primary Completion—

Lead SponsorProMis Neurosciences, Inc

Data Retrieved2026-04-11 04:24:41.104221+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.